Skip to content

Systemic Mechanisms in Allergic Rhinitis: Assessment of Metabolomic Outcomes.

Systemic Mechanisms in Allergic Rhinitis: Assessment of Metabolomic Outcomes Using the Environmental Exposure Unit (EEU). Part 2.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02230475
Acronym
NMR
Enrollment
15
Registered
2014-09-03
Start date
2014-08-31
Completion date
2014-09-30
Last updated
2015-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis

Keywords

Allergic Rhinitis, NMR

Brief summary

This clinical study will use the Environmental Exposure Unit (EEU) to generate allergic rhinitis symptoms in participants under controlled conditions, to collect well-characterized biological samples (urine and blood) before and after they develop these symptoms. The EEU provides the ability to control the timing, duration and levels of allergen exposure, and also other outside environmental factors, yielding ideal biologic samples for analysis with novel, cutting-edge molecular techniques. Results from the analysis of these unique allergic rhinitis samples should help determine if the technique of urine Nuclear Magnetic Resonance analysis could be a useful diagnostic tool in allergic rhinitis. IgE testing will be done on blood samples and compared to spin prick testing and symptoms of allergic rhinitis.

Interventions

None listed

Sponsors

Queen's University
Lead SponsorOTHER

Study design

Observational model
COHORT

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Participant is a healthy, ambulatory male or female volunteer 18 to 55 years of age. * Participant has a history of Seasonal Allergic Rhinitis due to ragweed for the last two consecutive ragweed seasons. * Participant has a positive response (wheal diameter greater than or equal to 3 mm larger than diluent control) to a skin prick test to short ragweed allergen at screening or within 12 months of screening visit.

Exclusion criteria

* Participant is a female that is pregnant, lactating or actively trying to become pregnant. * smokers * Participant is unable to comply with the washout periods for prohibited medications. * Participant is currently receiving allergen specific immunotherapy injections.

Design outcomes

Primary

MeasureTime frameDescription
MetabolomicsParticipant visits from July 2014 - September 2014; samples and data will be analyzed and presented for up to 2 years following participant visits.Determine if urine NMR metabolic profiles from participants with allergic rhinitis will be significantly different from that of healthy participants (healthy controls were included in part 1 of the 2010 study) and if changes in urine NMR profile correlate with disease severity. NMR will be reported

Secondary

MeasureTime frameDescription
IgE testingParticipant visits from July 2014 - September 2014; samples and data will be analyzed and presented for up to 2 years following participant visits.Blood samples will be collected from participants to measure ragweed specific IgE levels and compare them to their individual skin testing wheal size as well as their symptoms of allergic rhinitis in the EEU before and after pollen exposure. These symptoms are reported on a questionnaire completed by the participant every 20 minutes.
EpigeneticsParticipant visits from July 2014 - September 2014; samples and data will be analyzed and presented for up to 2 years following participant visits.Blood samples will be collected to examine epigenetic biomarkers in relation to symptoms of allergic rhinitis before and after exposure in the EEU. These symptoms are reported on a questionnaire completed by the participant every 20 minutes.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026